vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and ROGERS CORP (ROG). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $200.5M, roughly 1.4× ROGERS CORP). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 2.2%, a 94.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 5.2%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -3.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
ACAD vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $200.5M |
| Net Profit | $273.6M | $4.5M |
| Gross Margin | 90.8% | 32.2% |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | 2.2% |
| Revenue YoY | 9.4% | 5.2% |
| Net Profit YoY | 90.3% | 421.4% |
| EPS (diluted) | $1.61 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $284.0M | $201.5M | ||
| Q3 25 | $278.6M | $216.0M | ||
| Q2 25 | $264.6M | $202.8M | ||
| Q1 25 | $244.3M | $190.5M | ||
| Q4 24 | $259.6M | $192.2M | ||
| Q3 24 | $250.4M | $210.3M | ||
| Q2 24 | $242.0M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $273.6M | $4.6M | ||
| Q3 25 | $71.8M | $8.6M | ||
| Q2 25 | $26.7M | $-73.6M | ||
| Q1 25 | $19.0M | $-1.4M | ||
| Q4 24 | $143.7M | $-500.0K | ||
| Q3 24 | $32.8M | $10.7M | ||
| Q2 24 | $33.4M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 90.8% | 31.5% | ||
| Q3 25 | 92.2% | 33.5% | ||
| Q2 25 | 92.2% | 31.6% | ||
| Q1 25 | 91.7% | 29.9% | ||
| Q4 24 | 91.6% | 32.1% | ||
| Q3 24 | 92.5% | 35.2% | ||
| Q2 24 | 92.5% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | 3.5% | ||
| Q3 25 | 12.8% | 7.3% | ||
| Q2 25 | 12.2% | -33.3% | ||
| Q1 25 | 7.9% | -0.2% | ||
| Q4 24 | 59.1% | -6.6% | ||
| Q3 24 | 12.6% | 6.9% | ||
| Q2 24 | 12.6% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | 96.3% | 2.3% | ||
| Q3 25 | 25.8% | 4.0% | ||
| Q2 25 | 10.1% | -36.3% | ||
| Q1 25 | 7.8% | -0.7% | ||
| Q4 24 | 55.4% | -0.3% | ||
| Q3 24 | 13.1% | 5.1% | ||
| Q2 24 | 13.8% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $1.61 | $0.20 | ||
| Q3 25 | $0.42 | $0.48 | ||
| Q2 25 | $0.16 | $-4.00 | ||
| Q1 25 | $0.11 | $-0.08 | ||
| Q4 24 | $0.86 | $-0.04 | ||
| Q3 24 | $0.20 | $0.58 | ||
| Q2 24 | $0.20 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $195.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $1.2B |
| Total Assets | $1.6B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $177.7M | $197.0M | ||
| Q3 25 | $258.0M | $167.8M | ||
| Q2 25 | $253.6M | $157.2M | ||
| Q1 25 | $217.7M | $175.6M | ||
| Q4 24 | $319.6M | $159.8M | ||
| Q3 24 | $155.1M | $146.4M | ||
| Q2 24 | $177.1M | $119.9M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $917.3M | $1.2B | ||
| Q2 25 | $822.4M | $1.2B | ||
| Q1 25 | $765.2M | $1.3B | ||
| Q4 24 | $732.8M | $1.3B | ||
| Q3 24 | $577.2M | $1.3B | ||
| Q2 24 | $516.7M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.1B | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $976.9M | $1.5B | ||
| Q2 24 | $914.1M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $5.8M |
| Free Cash FlowOCF − Capex | — | $1.1M |
| FCF MarginFCF / Revenue | — | 0.5% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-48.7M | $46.9M | ||
| Q3 25 | $74.3M | $28.9M | ||
| Q2 25 | $64.0M | $13.7M | ||
| Q1 25 | $20.3M | $11.7M | ||
| Q4 24 | $40.4M | $33.7M | ||
| Q3 24 | $63.2M | $42.4M | ||
| Q2 24 | $25.0M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | — | $42.2M | ||
| Q3 25 | $73.9M | $21.2M | ||
| Q2 25 | — | $5.6M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | $63.2M | $25.2M | ||
| Q2 24 | — | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | — | 20.9% | ||
| Q3 25 | 26.5% | 9.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | 25.2% | 12.0% | ||
| Q2 24 | — | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | 0.0% | 8.2% | ||
| Q2 24 | — | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | -0.18× | 10.20× | ||
| Q3 25 | 1.03× | 3.36× | ||
| Q2 25 | 2.40× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | 3.96× | ||
| Q2 24 | 0.75× | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
ROG
Segment breakdown not available.
